Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment

Addiction Biology

Volumn 18, Issue 1, 2013, Pages 193-201

  Kranzler, Henry R ^a   Armeli, Stephen ^b   Covault, Jonathan ^c   Tennen, Howard ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Desire to drink; heavy drinking; naltrexone; pharmacogenetics; treatment response

Indexed keywords

NALTREXONE; PLACEBO;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; FEMALE; GENE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPRM1 GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TELECONSULTATION;

ADOLESCENT; ADULT; AGED; ALCOHOL DRINKING; ALCOHOLISM; ALLELES; COUNSELING; DATA INTERPRETATION, STATISTICAL; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MEDICAL RECORDS; MIDDLE AGED; MOTIVATION; NALTREXONE; NARCOTIC ANTAGONISTS; PHARMACOGENETICS; PLACEBOS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871803891     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2012.00471.x     Document Type: Article

References (30)

1. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D, (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65: 135-144.
2. Arias A, Feinn R, Kranzler HR, (2006) Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 83: 262-268.
3. Armeli S, Tennen H, Affleck G, Kranzler HR, (2000) Does affect mediate the association between daily events and alcohol use? J Stud Alcohol 61: 862-871.
4. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D, (1997) Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 2: 490-494.
5. Coller JK, Cahill S, Edmonds C, Farquharson AL, Longo M, Minniti R, Sullivan T, Somogyi AA, White JM, (2011) OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenet Genomics 21: 902-905.
6. Coxe S, West SG, Aiken LS, (2009) The analysis of count data: a gentle introduction to Poisson regression and its alternatives. J Pers Assess 91: 121-136.
7. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH, (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31: 555-563.
8. Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, Kim JG, Choi YS, Kim HO, Kim SY, Oslin DW, (2009) A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl) 201: 611-618.
9. Kranzler H, Edenberg H, (2010) Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des 16: 2141-2148.
10. Kranzler HR, Abu-Hasaballah K, Tennen H, Feinn R, Young K, (2004) Using daily interactive voice response technology to measure drinking and related behaviors in a pharmacotherapy study. Alcohol Clin Exp Res 28: 1060-1064.
11. Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, Pettinati H, Oncken C, (2011) A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol 31: 22-30.
12. Kranzler HR, Tennen H, Armeli S, Chan G, Covault J, Arias A, Oncken C, (2009) Targeted naltrexone for problem drinkers. J Clin Psychopharmacol 29: 350-357.
13. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R, Jr, (2006) Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 30: 1288-1296.
14. Mitchell JM, Fields HL, White RL, Meadoff TM, Joslyn G, Rowbotham MC, (2007) The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers. J Clin Psychopharmacol 27: 112-115.
15. Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, Daoust M, van den, Brink W, (2009) Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol 14: 328-337.
16. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP, (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28: 1546-1552.
17. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M, (2011) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16: 809-817.
18. Ray LA, (2011) Stress-induced and cue-induced craving for alcohol in heavy drinkers: preliminary evidence of genetic moderation by the OPRM1 and CRH-BP genes. Alcohol Clin Exp Res 35: 166-174.
19. Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF, (2012a) The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res 36: 385-394.
20. Ray LA, Bujarski S, Chin PF, Miotto K, (2012b) Pharmacogenetics of naltrexone in Asian Americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology 37: 445-455.
21. Ray LA, Hutchison KE, (2004) A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28: 1789-1795.
22. Ray LA, Hutchison KE, (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64: 1069-1077.
23. Ray LA, Miranda R, Jr, Tidey JW, McGeary JE, MacKillop J, Gwaltney CJ, Rohsenow DJ, Swift RM, Monti PM, (2010) Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. J Abnorm Psychol 119: 115-125.
24. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M, (2010) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev (12): CD001867.
25. Setiawan E, Pihl RO, Cox SM, Gianoulakis C, Palmour RM, Benkelfat C, Leyton M, (2011) The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. Alcohol Clin Exp Res 35: 1134-1141.
26. Sobell L, Sobell M, (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption. In:, Litten R, Allen J, eds. Measuring alcohol consumption, pp. 41-72. Clifton: Human Press.
27. Stone A, Shiffman S, (1994) Ecological momentary assessment (EMA) in behavioral medicine. Ann Behav Med 16: 199-202.
28. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R, Jr, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA, (2008) Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32: 58-66.
29. Todd M, Armeli S, Tennen H, Carney MA, Affleck G, (2003) A daily diary validity test of drinking to cope measures. Psychol Addict Behav 17: 303-311.
30. van den Wildenberg E, Wiers RW, Dessers J, Janssen RG, Lambrichs EH, Smeets HJ, van, Breukelen GJ, (2007) A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 31: 1-10.